Additional information:
Indole-3-acetamide is a biosynthesis intermediate of indole-3-acetic acid (HY-18569). Indole-3-acetic acid is the most common natural plant growth hormone of the auxin class.|Product information|CAS Number: 879-37-8|Molecular Weight: 174.Lamivudine supplier 20|Formula: C10H10N2O|Chemical Name: 2-(1H-indol-3-yl)acetamide|Smiles: NC(=O)CC1=CNC2C=CC=CC=21|InChiKey: ZOAMBXDOGPRZLP-UHFFFAOYSA-N|InChi: InChI=1S/C10H10N2O/c11-10(13)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,12H,5H2,(H2,11,13)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: H2O : 1.PMID:31971712 3 mg/mL (7.46 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|

Additional information:
Oxyresveratrol (trans-Oxyresveratrol) is a potent naturally occurring antioxidant and free radical scavenger (IC50 of 28.9 µM against DPPH free radicals). Oxyresveratrol is potent and noncompetitive tyrosinase inhibitor with an IC50 value of 1.2 µM for mushroom tyrosinase. Oxyresveratrol is effective against HSV-1, HSV-2 and varicella-zoster virus, and has neuroprotective effects.|Product information|CAS Number: 29700-22-9|Molecular Weight: 244.24|Formula: C14H12O4|Chemical Name: 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol|Smiles: OC1C=C(O)C(/C=C/C2C=C(O)C=C(O)C=2)=CC=1|InChiKey: PDHAOJSHSJQANO-OWOJBTEDSA-N|InChi: InChI=1S/C14H12O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h1-8,15-18H/b2-1+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (204.72 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Thyrotropin Autophagy |Shelf Life: ≥12 months if stored properly.PMID:33136544 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Cultures of the murine microglial cell line N9 and primary mixed glial cultures were used to test the drug effects of NO production upon expression of the inducible isoform of nitric oxide synthase (iNOS). Oxyresveratrol considerably diminished NO (nitrite) levels (IC50 of 45.31 µM) in murine microglial cells. Oxyresveratrol can inhibit DOPA oxidase activity, cyclooxygenase, and rat liver mitochondrial ATPase activity. Oxyresveratrol exhibits 63.3% inhibition at 100 µM and an IC50 value of 52.7 µM on the murine tyrosinase activity. Oxyresveratrol exhibits a dose-dependent inhibitory effect on L-tyrosine oxidation by the murine tyrosinase but does not inhibit the promoter activity of the enzyme gene. Oxyresveratrol exhibits significant inhibitory effects at 10 µM and higher concentrations on murine tyrosinase activity.|In Vivo:|Oxyresveratrol (2-30 mg/kg; intraperitoneal injection; twice) treatment reduces the brain infarct volume in MCAO rats. Oxyresveratrol treatment diminishes cytochrome c release and decreased caspase-3 activation, and reduces the number of apoptotic nuclei in ischemic brain in MCAO rats.|Products are for research use only. Not for human use.|

Additional information:
Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and Product information|CAS Number: 1216621-00-9|Molecular Weight: 434.01|Formula: C24H36ClN3O2|Chemical Name: 1-[1-(cyclooctylmethyl)-5-(hydroxymethyl)-1,2,3,6-tetrahydropyridin-4-yl]-3-ethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one hydrochloride|Smiles: Cl.CCN1C(=O)N(C2=CC=CC=C12)C1CCN(CC2CCCCCCC2)CC=1CO|InChiKey: YEVMLMQAMCKVSC-UHFFFAOYSA-N|InChi: InChI=1S/C24H35N3O2.ClH/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19;/h8-9,12-13,19,28H,2-7,10-11,14-18H2,1H3;1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Trap-101 hydrochloride (3, 30, and 300 nM) is inactive per se up to 10 μM, while in the range 3-300 nM, it produces a concentration dependent rightward shift of the concentration-response curve to N/OFQ without modifications of the maximal response to the agonist.Dacomitinib Formula Receptor binding affinities of Trap101 (pKi values) at recombinant human NOP, and classical opioid receptors expressed in CHO cell membranes are 8.Citric acid custom synthesis 65, 6.PMID:32806977 60, 6.14 and In Vivo:|Trap-101 hydrochloride (10-30 mg/kg; detected after 90 min) changes motor activity in naïve rats, it causes a delayed increase in the immobility time in the bar test at 30 mg/kg, Moreover, it increased stepping activity and rotarod performance at 10 mg/kg and reduces them at 30 mg/kg. 6-OHDA lesioning produces motor asymmetry mostly affecting the contralateral paw and overall reduced motor performance. Trap-101 hydrochloride (intraperitoneal injection; 10-30 mg/kg; detected after 90 min) alleviates akinesia/bradykinesia and improves overall gait ability in hemiparkinsonian rats, being effective starting at 1 mg/kg and without worsening motor deficit at 30 mg/kg.|Products are for research use only. Not for human use.|

Additional information:
TAS6417 (CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM.|Product information|CAS Number: 1661854-97-2|Molecular Weight: 396.44|Formula: C23H20N6O|Chemical Name: N-[(8S)-4-amino-6-methyl-5-(quinolin-3-yl)-8H,9H-pyrimido[5,4-b]indolizin-8-yl]prop-2-enamide|Smiles: CC1=C[C@@H](CN2C3=NC=NC(N)=C3C(=C21)C1C=NC2=CC=CC=C2C=1)NC(=O)C=C|InChiKey: MKCYPWYURWOKST-INIZCTEOSA-N|InChi: InChI=1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 22.Abrocitinib Epigenetics 73 mg/mL (57.Aloe emodin Autophagy 34 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:31985982 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TAS6417 inhibits EGFR phosphorylation and downstream molecules in NSCLC cell lines expressing EGFR exon 20 insertions, resulting in caspase activation. TAS6417 is a robust inhibitor against the most common EGFR mutations (exon 19 deletions and L858R) and the most potent against cells harboring EGFR-T790M (1st/2nd generation TKI resistance mutation). TAS6417 covalently modified the cysteine residue at position 797 of recombinant EGFR harboring an in-frame insertion mutation in the exon 20 region. TAS6417 inhibits EGFR signal transduction, leading to cell growth inhibition and apoptosis induction in NSCLC cells driven by EGFR exon 20 insertion mutations. TAS6417 (0-10 μM) inhibits cell proliferation and EGFR signaling in NSCLC cell lines harboring EGFR common mutations in the presence or absence of T790M.|In Vivo:|TAS6417 (10-200 mg/kg) causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models. TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues. TAS6417 had no effect on EGFR-independent proliferation in NCI-H23 or NCI-H460 cells. TAS6417 administered at 20 mg/kg, which achieves complete suppression of tumor growth, induces a significant decrease in pEGFR, leading to reduction of pAKT and pERK at 1 h. The inhibitory effect is still noted at 6 h, and phosphorylation of EGFR, ATK, and ERK recovered by 24 h. TAS6417 (100 and 200 mg/kg/day) prolongs survival of animals bearing lung cancer.|Products are for research use only. Not for human use.|

Additional information:
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist.PMID:33219011 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM.|Product information|CAS Number: 87893-55-8|Molecular Weight: 316.43|Formula: C20H28O3|Chemical Name: (5E)-7-[(1S,5Z)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid|Smiles: CCCCC/C=C/C=C1/[C@@H](C/C=C/CCCC(O)=O)C=CC/1=O|InChiKey: VHRUMKCAEVRUBK-XOVNXQNQSA-N|InChi: InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7+,10-6+,18-13-/t17-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|15-Deoxy-Δ12,14-PGJ2 (15d-PGJ2) is a cyclopentenone prostaglandin that features an electrophilic, α, β-unsaturated ketone (an enone) in the cyclopentenone ring. 15-Deoxy-Δ-12,14-prostaglandin J2 is one of the cyPGs whose functions in inflammation, cell proliferation, survival, and apoptosis have been documented. 15-Deoxy-Δ-12,14-prostaglandin J2 activates PPARδ in a dose-dependent manner. 15-Deoxy-Δ-12,14-prostaglandin J2 activates PPARδ’s transcriptional activity through formation of a covalent adduct between its endocyclic enone at C9 and Cys249 in the receptor’s ligand-binding domain.|Products are for research use only. Not for human use.|